Barometer Capital Management Inc. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Barometer Capital Management Inc. bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 1st quarter, Holdings Channel.com reports. The fund bought 77,800 shares of the company’s stock, valued at approximately $2,343,000. Teva Pharmaceutical Industries accounts for about 1.0% of Barometer Capital Management Inc.’s portfolio, making the stock its 28th largest holding.

Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth about $1,098,060,000. WCM Investment Management LLC raised its stake in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Teva Pharmaceutical Industries by 39,228.4% during the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after buying an additional 6,878,304 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $31.36 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The firm’s 50-day moving average price is $33.57 and its two-hundred day moving average price is $32.70. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The stock has a market capitalization of $36.05 billion, a P/E ratio of 23.58, a P/E/G ratio of 3.27 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the sale, the executive vice president directly owned 172,184 shares in the company, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Bank of America upped their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Truist Financial raised their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.